FDA Accepts Biologics License Application For Aimovig ™ (erenumab)

Aimovig is an Investigative Migraine-Specific Preventive Therapy Designed for Patients With High Unmet Need Migraine is Associated With Pain, Disability and Nearly $25 Billion in Annual U.S. Healthcare Costs[1],[2] THOUSAND OAKS, Calif., July 20, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Aimovig™ (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. If approved, Aimovig is expected to be the first-and-only monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, specifically desi...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news